LINFOMA ESPLENICO DE LA ZONA MARGINAL PDF

Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.

Author: Kazrahn Kizuru
Country: Benin
Language: English (Spanish)
Genre: Education
Published (Last): 26 June 2018
Pages: 498
PDF File Size: 5.41 Mb
ePub File Size: 9.21 Mb
ISBN: 591-7-19391-129-6
Downloads: 36737
Price: Free* [*Free Regsitration Required]
Uploader: Yotaur

Health care resources for this disease Expert centres Diagnostic tests 59 Patient organisations 45 Orphan drug s A new course of rituximab was administered, using the same schedule as before.

None Sources of funding: From these cases, it can be suggested that postponement of cytotoxic treatments may be possible in at least some situations.

World health organization classification of tumours. CiteScore measures average citations received per document published.

Procesos linfoproliferativos no Hodgkin de células B

Catovsky D, Matutes E. Rituximab should be considered in patients who are poor candidates for splenectomy. However, a few patients relapse and the second-line treatment remains questionable.

Curr Treat Options Oncol. Linfoma B de la zona marginal.

  INTRODUCTORY NUCLEAR PHYSICS K.S.KRANE PDF

The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene. The treatment was well tolerated.

Linfoma esplénico de la zona marginal:

Rituximab monotherapy also controlled the autoimmune thrombocytopenia in one patient. It should be noted that a broader d strategy was used in relation to these last two databases Table 1. The diagnosis was established using standard criteria. She received the monoclonal antibody following the same schedule as used for our other patient, described above. Read this article in English.

Linfoma esplénico de la zona marginal

At this time, the patient was referred to our center, and we decided to avoid chemotherapy and start rituximab as a single agent, because she presented with a creatinine level slightly over the normal range.

Es un tumor indolente, no curable.

Linfooma approach to classifying non-Hodgkin’s lymphomas: Intrasinusoidal bone marrow infiltration: Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone B-cell lymphoma. Skin involvement by splenic MZL is uncommon; this form of the disease can present epidermotropism, a very rare finding in primary cutaneous MZL.

Orphanet: Linfoma esplenico de la zona marginal

Furthermore it could constitute an alternative to splenectomy in older patients. Translocation t 11;14 q13;q32 in chronic lymphoid disorders. Splenic marginal zone lymphoma with and without villous lymphocytes. Splenic marginal zone lymphoma: Br J Wsplenico Oct;99 1: Rituximab with or without chemotherapy was found to have major activity in patients with SMZL. If you are a member of the AEDV: Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.

  GOODMAN AND GILMAN THE PHARMACOLOGICAL BASIS OF THERAPEUTICS 12E PDF

The median number of CD20 molecules per cell was 69 x 10 3. One CR and seven minor or good haematological esponses were recorded in relapsed patients. Am J Clin Pathol.

September 27, Conflict of interest: The workup revealed disease in the peripheral blood and bone marrow and massive splenomegaly. Patients with asymptomatic disease are generally managed using a watch-and-wait strategy, while the majority of symptomatic individuals undergo splenectomy or splenic irradiationand eslpenico few receive front-line chemotherapy, especially with purine analogues. Prognostic value of numerical chromosome aberrations in multiple myeloma: SMZL was confirmed in 70 patients.